We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FDA Accepts Regeneron/Sanofi's Dupixent sBLA for Asthma
Read MoreHide Full Article
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) and partner Sanofi (SNY - Free Report) announced that the FDA has accepted for review the supplemental Biologics License Application (sBLA) of Dupixent (dupilumab) as an add-on maintenance treatment in adults and adolescents (12 years of age or older) with moderate-to-severe asthma.
The FDA has set a target action date of Oct 20, 2018 per the Prescription Drug User Fee Act. The sBLA was supported by results from the three pivotal trials from the LIBERTY ASTHMA clinical development program.
We note that Dupixent was approved in the United States in March 2017 for the treatment of adults with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Dupixent is also approved for use in certain patients with moderate-to-severe atopic dermatitis in a number of other countries, including the European Union, Canada and Japan.
Dupixent uptake in the United States for moderate-to-severe atopic dermatitis was encouraging. Dupixent sales came in at $139 million in the fourth quarter. A potential label expansion of the drug will further boost results.
Meanwhile, Sanofi and Regeneron are studying dupilumab in a broad range of clinical development programs for diseases driven by Type 2 inflammation, including pediatric atopic dermatitis (phase III), nasal polyps (phase III) and eosinophilic esophagitis (phase III).
Regeneron’s stock has lost 33.8% in the last six months compared with the industry’s 9.8% decline.
Regeneron’s growth driver Eylea continues to perform well. Regeneron has co-developed Eylea with the HealthCare unit of Bayer AG (BAYRY - Free Report) . The potential label expansion of Eylea in patients with wet age-related macular degeneration will further boost sales. The action date set by the FDA is Aug 11, 2018.
Zacks Rank & Another Key Pick
Regeneron currently sports a Zacks Rank #1 (Strong Buy).
Ligand’s earnings per share estimates have moved up from $3.78 to $4.15 for 2018 in the last 30 days. The company delivered a positive earnings surprise in three out of the trailing four quarters, with an average beat of 24.88%.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
FDA Accepts Regeneron/Sanofi's Dupixent sBLA for Asthma
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) and partner Sanofi (SNY - Free Report) announced that the FDA has accepted for review the supplemental Biologics License Application (sBLA) of Dupixent (dupilumab) as an add-on maintenance treatment in adults and adolescents (12 years of age or older) with moderate-to-severe asthma.
The FDA has set a target action date of Oct 20, 2018 per the Prescription Drug User Fee Act. The sBLA was supported by results from the three pivotal trials from the LIBERTY ASTHMA clinical development program.
We note that Dupixent was approved in the United States in March 2017 for the treatment of adults with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Dupixent is also approved for use in certain patients with moderate-to-severe atopic dermatitis in a number of other countries, including the European Union, Canada and Japan.
Dupixent uptake in the United States for moderate-to-severe atopic dermatitis was encouraging. Dupixent sales came in at $139 million in the fourth quarter. A potential label expansion of the drug will further boost results.
Meanwhile, Sanofi and Regeneron are studying dupilumab in a broad range of clinical development programs for diseases driven by Type 2 inflammation, including pediatric atopic dermatitis (phase III), nasal polyps (phase III) and eosinophilic esophagitis (phase III).
Regeneron’s stock has lost 33.8% in the last six months compared with the industry’s 9.8% decline.
Regeneron’s growth driver Eylea continues to perform well. Regeneron has co-developed Eylea with the HealthCare unit of Bayer AG (BAYRY - Free Report) . The potential label expansion of Eylea in patients with wet age-related macular degeneration will further boost sales. The action date set by the FDA is Aug 11, 2018.
Zacks Rank & Another Key Pick
Regeneron currently sports a Zacks Rank #1 (Strong Buy).
Another top-ranked stock in the health care sector is Ligand Pharmaceuticals Inc. (LGND - Free Report) which carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Ligand’s earnings per share estimates have moved up from $3.78 to $4.15 for 2018 in the last 30 days. The company delivered a positive earnings surprise in three out of the trailing four quarters, with an average beat of 24.88%.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>